Dare Bioscience, Inc. (NASDAQ:DARE)
| Market Cap | $8.01M-75.8% |
| Revenue (ttm) | $1.41M+2570.3% |
| Net Income | -$10.58M+39.4% |
| EPS | -$0.69+63.3% |
| Shares Out | 19.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 173,237 |
| Open | $0.44 |
| Previous Close | $0.45 |
| Day's Range | $0.41 - $0.44 |
| 52-Week Range | $0.41 - $3.78 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | $1.50(+268.19%) |
| Earnings Date | Mar 25, 2027 |
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 25, 2027Earnings report
$DARE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in DARE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DARE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DARE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
DARE Revenue by Segment
| Direct program costs: | $1.03M | 76.28% |
| Indirect costs: | $318.91K | 23.72% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New DARE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DARE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DARE
| VTIVanguard Morningstar Total Stock Market ETF | $259.93K |
| VXFVanguard Extended Market ETF | $112.90K |
| IWCiShares Micro-Cap ETF | $18.58K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from DARE’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 revenue miss offset by first product sales milestone, grant funding, and pipeline progress; mixed results with early commercial traction.
